164 related articles for article (PubMed ID: 25681288)
41. In vitro and in vivo experiments on electrochemotherapy for bladder cancer.
Vásquez JL; Ibsen P; Lindberg H; Gehl J
J Urol; 2015 Mar; 193(3):1009-15. PubMed ID: 25245485
[TBL] [Abstract][Full Text] [Related]
42. [Effects of survivin small interfering RNA on biological behaviors of bladder cancer T24 cells].
Wang XL; Hou JQ; Wen DG; He J
Ai Zheng; 2008 Mar; 27(3):253-7. PubMed ID: 18334113
[TBL] [Abstract][Full Text] [Related]
43. Antitumor activity of a novel survivin siRNA.
Li Y; Li Y; Lee RJ; Wang X; Du L; Zhao L; Liu Y; Teng L
Pak J Pharm Sci; 2015 Sep; 28(5 Suppl):1887-90. PubMed ID: 26525031
[TBL] [Abstract][Full Text] [Related]
44. Engagement of integrinβ1 induces resistance of bladder cancer cells to mitomycin-C.
Zhang CJ; Shen ZJ; Pan CW; Zhong S; Li T; Zhang MG
Urology; 2012 Mar; 79(3):638-43. PubMed ID: 22386417
[TBL] [Abstract][Full Text] [Related]
45. Over expression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy.
Lynn NN; Howe MC; Hale RJ; Collins GN; O'Reilly PH
J Urol; 2003 Feb; 169(2):721-3. PubMed ID: 12544351
[TBL] [Abstract][Full Text] [Related]
46. Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma.
Mullerad M; Bochner BH; Adusumilli PS; Bhargava A; Kikuchi E; Hui-Ni C; Kattan MW; Chou TC; Fong Y
J Urol; 2005 Aug; 174(2):741-6. PubMed ID: 16006968
[TBL] [Abstract][Full Text] [Related]
47. Survivin siRNA inhibits gastric cancer in nude mice.
Wenying Z; Zhaoning J; Zhimin Y; Dongyun C; Lili S
Cell Biochem Biophys; 2012 Mar; 62(2):337-41. PubMed ID: 22052003
[TBL] [Abstract][Full Text] [Related]
48. Prevention and treatment of transitional cell carcinomatosis with intraperitoneal chemotherapy in a rat model.
Abaza R; Miocinovic R; Keck RW; Selman SH
J Urol; 2009 Apr; 181(4):1901-6. PubMed ID: 19237166
[TBL] [Abstract][Full Text] [Related]
49. Reducing recurrence and costs in superficial bladder cancer: preclinical evaluation of osmotic cytolysis by distilled water vs. mitomycin.
Fechner G; Pocha K; Schmidt D; Müller SC
Int J Clin Pract; 2006 Oct; 60(10):1178-80. PubMed ID: 16669821
[TBL] [Abstract][Full Text] [Related]
50. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
Mahalingam D; Medina EC; Esquivel JA; Espitia CM; Smith S; Oberheu K; Swords R; Kelly KR; Mita MM; Mita AC; Carew JS; Giles FJ; Nawrocki ST
Clin Cancer Res; 2010 Jan; 16(1):141-53. PubMed ID: 20028765
[TBL] [Abstract][Full Text] [Related]
51. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
52. RNA interference-mediated vascular endothelial growth factor-C reduction suppresses malignant progression and enhances mitomycin C sensitivity of bladder cancer T24 cells.
Zhang HH; Qi F; Shi YR; Miao JG; Zhou M; He W; Chen MF; Li Y; Zu XB; Qi L
Cancer Biother Radiopharm; 2012 Jun; 27(5):291-8. PubMed ID: 21902544
[TBL] [Abstract][Full Text] [Related]
53. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts.
Takei Y; Kadomatsu K; Goto T; Muramatsu T
Cancer; 2006 Aug; 107(4):864-73. PubMed ID: 16832814
[TBL] [Abstract][Full Text] [Related]
54. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
55. Polypurine reverse Hoogsteen hairpins as a gene therapy tool against survivin in human prostate cancer PC3 cells in vitro and in vivo.
Rodríguez L; Villalobos X; Dakhel S; Padilla L; Hervas R; Hernández JL; Ciudad CJ; Noé V
Biochem Pharmacol; 2013 Dec; 86(11):1541-54. PubMed ID: 24070653
[TBL] [Abstract][Full Text] [Related]
56. [Inhibition of bladder cancer cell growth and angiogenesis by co-blockage of vascular endothelial growth factor and its receptor KDR].
Chen XL; Liu LC; Xu ZG; Li Z; Li RW; Gao RJ; Wang S; Zhang M; Guo H
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):578-82. PubMed ID: 19102933
[TBL] [Abstract][Full Text] [Related]
57. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers.
Li QX; Zhao J; Liu JY; Jia LT; Huang HY; Xu YM; Zhang Y; Zhang R; Wang CJ; Yao LB; Chen SY; Yang AG
Cancer Biol Ther; 2006 Jul; 5(7):860-6. PubMed ID: 16861916
[TBL] [Abstract][Full Text] [Related]
58. Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures.
Yen WC; Schmittgen T; Au JL
Pharm Res; 1996 Dec; 13(12):1887-91. PubMed ID: 8987090
[TBL] [Abstract][Full Text] [Related]
59. RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo.
Hendruschk S; Wiedemuth R; Aigner A; Töpfer K; Cartellieri M; Martin D; Kirsch M; Ikonomidou C; Schackert G; Temme A
Neuro Oncol; 2011 Oct; 13(10):1074-89. PubMed ID: 21788344
[TBL] [Abstract][Full Text] [Related]
60. The effects of STAT3 and Survivin silencing on the growth of human bladder carcinoma cells.
Zhang B; Lu Z; Hou Y; Hu J; Wang C
Tumour Biol; 2014 Jun; 35(6):5401-7. PubMed ID: 24519067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
